SCHEMBL26459002

SCHEMBL26459002

O=C1S/C(=C/C=C/c2ccco2)C(=O)N1c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 15/20 1.00
▸ MEN1 O00255 14/20 1.00
▸ KMT2A Q03164 14/20 1.00
▸ POLB P06746 13/20 1.00
▸ L3MBTL1 Q9Y468 12/20 1.00
▸ RECQL P46063 12/20 1.00
▸ KDM4E B2RXH2 10/20 1.00
▸ ALDH1A1 P00352 7/20 1.00
▸ LMNA P02545 3/20 1.00
▸ HTT P42858 3/20 1.00
▸ RAB9A P51151 2/20 1.00
▸ NPC1 O15118 1/20 1.00
▸ USP2 O75604 10/20 0.80
▸ BLM P54132 8/20 0.80
▸ ALOX12 P18054 3/20 0.80
▸ ALOX5 P09917 1/20 0.71
▸ APEX1 P27695 6/20 0.63
▸ MCL1 Q07820 6/20 0.63
▸ ALPL P05186 4/20 0.63
▸ ALPI P09923 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2985626 0.84 MEN1 (0.76) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL8172936 0.77 MAPT (0.64) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL5993381 0.73 MEN1 (0.60) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL26485785 0.73 MAPT (0.65) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL5991599 0.72 MEN1 (0.75) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL17833967 0.72 MAPT (0.67) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL3012532 0.71 MEN1 (1.00) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL17229211 0.71 KMT2A (0.82) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL17834314 0.70 MEN1 (0.63) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL14680208 0.69 MAPT (1.00) MAPTMEN1KMT2APOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2023-11-16 — — US disclosed
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2023-11-16 — — US disclosed
US-20230136466-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-05-04 — — US disclosed
US-20230136466-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF TOP1, DNA2, TOP2A MAPT 3260/4885MEN1 4457/4885KMT2A 2037/4885
US-20230136466-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF TOP1, DNA2, TOP2A MAPT 3260/4885MEN1 4457/4885KMT2A 2037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback